Cytokinetics to start phase 2 trial of CK-1827452 in heart failure patients before year end

By Jennifer Lanning Drey

Portland, Ore., Nov. 16 - Cytokinetics, Inc. will begin a phase 2 clinical trial before the end of the year for CK-1827452, a novel cardiac myosin activator that is administered intravenously, in heart failure patients, chief executive officer Dr. James H. Sabry said at the JMP Securities Healthcare Conference in Boston on Thursday.

The trial will be a randomized study examining dose response and is part of a larger phase 2 clinical program that will be made up of a series of small, highly focused studies, Sabry said.

The studies will be used to narrow down dose exploration, which will be further studied in a phase 2b program expected to begin at the end of 2007 or early 2008, he said.

Sabry also said that CK-1827452 was the subject of a recently completed oral bioavailability study, and the company will report top-line data from that study before the end of the year.

Cytokinetics also has three cancer products in development, the newest of which will enter the clinic in 2007, Sabry said Thursday.

Ispinesib, or SB-715992, which is Cytokinetics' most advanced cancer product, was the subject of a recently completed phase 2 study, and the company also expects to report top-line data from that study before the end of the year.

Cytokinetics' other oncology product, SB-743921 for lymphoma, will move into phase 2 trials next year, Sabry said.

Cytokinetics is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that target the cytoskeleton.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.